AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, β-amyloidosis, and learning impairment of APP/ PS1 mice

Molecular Therapy

Volumn 17, Issue 5, 2009, Pages 803-809

  Kiyota, Tomomi ^a,b   Yamamoto, Masaru ^a,b   Schroder, Bryce ^a,b   Jacobsen, Michael T ^a,b   Swan, Russell J ^a,b   Lambert, Mary P ^c   Klein, William L ^c   Gendelman, Howard E ^a,b   Ransohoff, Richard M ^d   Ikezu, Tsuneya ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GENE PRODUCT; MONOCYTE CHEMOTACTIC PROTEIN 1; PARVOVIRUS VECTOR; PRESENILIN 1; PROTEIN 7ND; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENETIC TRANSFECTION; GLIOSIS; LEARNING DISORDER; MOUSE; MUTANT; NONHUMAN; SEROTYPE; VIRAL GENE DELIVERY SYSTEM;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; CHEMOKINE CCL2; DEPENDOVIRUS; FEMALE; GLIOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; PRESENILIN-1;

ADENO-ASSOCIATED VIRUS; MUS; MUS MUSCULUS;

EID: 67349276438     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.44     Document Type: Article

References (50)

1. Barron, KD (1995). The microglial cell. A historical review. J Neurol Sci 134 (suppl.): 57-68.
2. Ikezu, T (2008). Alzheimer's disease. In: Ikezu T, Gendelman HE (eds). Neuroimmune Pharmacology. Springer: New York. pp. 343-353.
3. Akiyama, H, Barger, S, Barnum, S, Bradt, B, Bauer, J, Cole, GM et al (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
4. McGeer, PL and McGeer, EG (2001). Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22: 799-809.
5. Blasko, I, Marx, F, Steiner, E, Hartmann, T and Grubeck-Loebenstein, B (1999). TNF-α plus IFN-γ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. Faseb J 13: 63-68.
6. Yamamoto, M, Kiyota, T, Horiba, M, Buescher, JL, Walsh, SM, Gendelman, HE et al. (2007). Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant app transgenic mice. Am J Pathol 170: 680-692.
7. Yamamoto, M, Kiyota, T, Walsh, SM, Liu, J, Kipnis, J and Ikezu, T (2008). Cytokine-mediated inhibition of fibrillar amyloid-β peptide degradation by human mononuclear phagocytes. J Immunol 181: 3877-3886.
8. Tan, J, Town, T and Mullan, M (2002). CD40-CD40L interaction in Alzheimer's disease. Curr Opin Pharmacol 2: 445-451.
9. He, P, Zhong, Z, Lindholm, K, Berning, L, Lee, W, Lemere, C et al. (2007). Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178: 829-841.
10. Charo, IF, Myers, SJ, Herman, A, Franci, C, Connolly, AJ and Coughlin, SR (1994). Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 91: 2752-2756.
11. Calvo, CF, Yoshimura, T, Gelman, M and Mallat, M (1996). Production of monocyte chemotactic protein-1 by rat brain macrophages. Eur J Neurosci 8: 1725-1734.
12. Glabinski, AR, Balasingam, V, Tani, M, Kunkel, SL, Strieter, RM, Yong, VW et al. (1996). Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 156: 4363-4368.
13. Ishizuka, K, Kimura, T, Igata-yi, R, Katsuragi, S, Takamatsu, J and Miyakawa, T (1997). Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 51: 135-138.
14. Xia, MQ and Hyman, BT (1999). Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 5 32-41.
15. Grammas, P and Ovase, R (2001). Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 22 837-842.
16. Yamamoto, M, Horiba, M, Buescher, JL, Huang, D, Gendelman, HE, Ransohoff, RM et al. (2005). Overexpression of monocyte chemotactic protein-1/CCL2 in β-amyloid precursor protein transgenic mice show accelerated diffuse β-amyloid deposition. Am J Pathol 166: 1475-1485.
17. Hsiao, K, Chapman, P, Nilsen, S, Eckman, C, Harigaya, Y, Younkin, S et al. (1996). Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
18. Frautschy, SA, Yang, F, Irrizarry, M, Hyman, B, Saido, TC, Hsaio, K et al. (1998). Microglial Response to Amyloid Plaques in APPsw Transgenic Mice. Am J Pathol 152: 307-317.
19. Huang, D, Tani, M, Wang, J, Han, Y, He, TT, Weaver, J et al. (2002). Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice. J Neurosci 22: 10633-10642.
20. Zhang, YJ, Rutledge, BJ and Rollins, BJ (1994). Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 269: 15918-15924.
21. Ikeda, Y, Yonemitsu, Y, Kataoka, C, Kitamoto, S, Yamaoka, T, Nishida, K et al. (2002). Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 283: H2021-H2028.
22. Xiao, X, Li, J, McCown, TJ and Samulski, RJ (1997). Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 144: 113-124.
23. Dudus, L, Anand, V, Acland, GM, Chen, SJ, Wilson, JM, Fisher, KJ et al. (1999). Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res 39: 2545-2553.
24. Guy, J, Qi, X, Muzyczka, N and Hauswirth, WW (1999). Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol 117: 929-937.
25. Peel, AL and Klein, RL (2000). Adeno-associated virus vectors: Activity and applications in the CNS. J Neurosci Methods 98: 95-104.
26. Passini, MA, Watson, DJ, Vite, CH, Landsburg, DJ, Feigenbaum, AL and Wolfe, JH (2003). Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of β-glucuronidase-deficient mice. J Virol 77: 7034-7040.
27. Zhang, Y and Rollins, BJ (1995). A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 15: 4851-4855.
28. Duff, K, Eckman, C, Zehr, C, Yu, X, Prada, CM, Perez-tur, J et al. (1996). Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713.
29. Morgan, D, Diamond, DM, Gottschall, PE, Ugen, KE, Dickey, C, Hardy, J et al. (2000). Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
30. Tan, J, Town, T, Crawford, F, Mori, T, DelleDonne, A, Crescentini, R et al. (2002). Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5: 1288-1293.
31. Walsh, DM, Klyubin, I, Fadeeva, JV, Cullen, WK, Anwyl, R, Wolfe, MS et al. (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
32. Lesné, S, Koh, MT, Kotilinek, L, Kayed, R, Glabe, CG, Yang, A et al. (2006). A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-357.
33. Wilcock, DM, Rojiani, A, Rosenthal, A, Subbarao, S, Freeman, MJ, Gordon, MN et al. (2004). Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1: 24.
34. Yamamoto, M, Kiyota, T, Walsh, SM and Ikezu, T (2007). Kinetic analysis of aggregated amyloid-b peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice. J Neuroimmune Pharmacol 2: 213-221.
35. El Khoury, J, Toft, M, Hickman, SE, Means, TK, Terada, K, Geula, C et al. (2007). Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13 432-438.
36. + monocytes only under defined host conditions. Nat Neurosci 10 1544-1553.
37. Kumai, Y, Ooboshi, H, Takada, J, Kamouchi, M, Kitazono, T, Egashira, K et al. (2004). Anti-monocyte chemoattractant protein-1 gene therapy protects against focal brain ischemia in hypertensive rats. J Cereb Blood Flow Metab 24: 1359-1368.
38. Fukuchi, K, Tahara, K, Kim, HD, Maxwell, JA, Lewis, TL, Accavitti-Loper, MA et al. (2006). Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 23: 502-511.
39. Wang, YJ, Pollard, A, Zhong, JH, Dong, XY, Wu, XB, Zhou, HD et al. (2009). Intramuscular delivery of a single chain antibody gene reduces brain Aβ burden in a mouse model of Alzheimer's disease. Neurobiol Aging 30: 364-376.
40. Iwata, N, Mizukami, H, Shirotani, K, Takaki, Y, Muramatsu, S, Lu, B et al. (2004). Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-β peptide in mouse brain. J Neurosci 24: 991-998.
41. Carty, NC, Nash, K, Lee, D, Mercer, M, Gottschall, PE, Meyers, C et al. (2008). Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Aβ deposits in APP + PS1 transgenic mice. Mol Ther 16: 1580-1586.
42. Mouri, A, Noda, Y, Hara, H, Mizoguchi, H, Tabira, T and Nabeshima, T (2007). Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. Faseb J 21: 2135-2148.
43. Hara, H, Monsonego, A, Yuasa, K, Adachi, K, Xiao, X, Takeda, S et al (2004). Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimers Dis 6: 483-488.
44. Zhang, J, Wu, X, Qin, C, Qi, J, Ma, S, Zhang, H et al. (2003). A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14: 365-379.
45. Kim, J, Miller, VM, Levites, Y, West, KJ, Zwizinski, CW, Moore, BD et al. (2008). BRI2 (ITM2b) inhibits Aβ deposition in vivo. J Neurosci 28: 6030-6036.
46. Etminan, M, Gill, S and Samii, A (2003). Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ 327: 128.
47. Galasko, DR, Graff-Radford, N, May, S, Hendrix, S, Cottrell, BA, Sagi, SA et al. (2007). Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21: 292-299.
48. Kukar, TL, Ladd, TB, Bann, MA, Fraering, PC, Narlawar, R, Maharvi, GM et al. (2008). Substrate-targeting γ-secretase modulators. Nature 453: 925-929.
49. Klein, RL, Hamby, ME, Gong, Y, Hirko, AC, Wang, S, Hughes, JA et al (2002). Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 176: 66-74.
50. Oddo, S, Caccamo, A, Tran, L, Lambert, MP, Glabe, CG, Klein, WL et al (2006). Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J Biol Chem 281: 1599-1604.